Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.63 Analyst target: $10.00 Upside: 513.50%
TransCode Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development and commercialization of drugs for the treatment of metastatic diseases. The company is headquartered in Boston, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.